Member Info for Laura2022

Buy limits have now been cut compared to a week ago

You also LT andBmein

Looks like he buying more

Currently 20% up but expecting much more from pre Christmas purchases

Currently 40% up on my holdings

Knew this would get voted down

Like with WHI the CEO will have to stand down as vote of no confidence

Well done Gordon etc for keeping the tally

My 0.8 purchases looking timely

Even healthier would be sustained incremental price rise surely;)

Like 15p soon

Hydro Jen

Think youre going to be disappointed personally

11p ask now

Carolus

See section 6 of the RNS

best wishes

Approaching 200% up from 5p investments

Thanks Espen

And there it is

The TR1 did indeed add more

Llooks very interesting play

And there are good grounds for believing the revival will gather pace in 2026. The brutal shakeout over the last few years has left a core of higher quality, better capitalised companies better able to inspire investor confidence. As a junior market AIM is particularly well positioned to benefit from the prospect of lower interest rates that will ease the debt burden of smaller companies. And it is a particular focus of ongoing efforts by policy makers (across all major parties) and regulators to improve the competitiveness of London’s markets and direct more investment into UK assets.

In his annual review of the small cap sector Investors’ Chronicle associate editor Simon Thompson notes that UK equities continue to be undervalued relative to US shares, particularly AIM-listed tech. Plenty of opportunities exist for canny stockpickers amid the many small caps with low earnings multiples.

Khorud

Goos afternoon, what implications does this have plz

Following a stronger-than-expected end to FY25 and entering FY26 with record levels of contracted revenue, we’ve continued to build momentum across our pipeline. Over the year, we’ve diversified our client base, expanded into new therapeutic areas and modalities, and applied MIDD to some of the most complex challenges in modern R&D – including securing our first contracts in Biometrics.

• In oncology, we secured several new projects spanning a range of drug modalities and development stages. These included work with a new UK-based biotech developing Antibody–Drug Conjugates (ADCs), where mechanistic PK/PD approaches were used to inform optimal dosing ahead of a First-in-Human trial. We also supported the development of a first-in-class bifunctional antibody, applying pharmacokinetic modelling to predict human PK and guide progression into clinical studies.

• Our collaboration with a large global pharma partner also expanded this year, with a sizeable contract extension building on previous work using our Virtual Tumour platform. This programme focuses on optimising dose and scheduling for targeted oncology agents, including combinations across new indications. In parallel, we were pleased to begin working with a UK biotech specialising in AI-powered drug development, using the Virtual Tumour platform to guide dosing decisions for an advanced oncology programme.

• Our long-standing collaboration with Numab Therapeutics AG continued to grow, with several new programmes across immunology and immuno-oncology. This included modelling and simulation to support the preclinical development of a multi-specific antibody designed to activate anti-tumour immune responses, as well as PK/PD modelling to inform FiH dose selection for an antibody in Numab’s inflammation pipeline

Beyond oncology, we broadened our therapeutic footprint:

• This includes with new work in rheumatoid arthritis, applying population PK modelling to Phase 1 data to inform Phase 2 trial design decisions. We also secured a contract supporting the development of renal disease therapies, establishing an early modelling and simulation strategy to guide future development.

And within our growing Biometrics service line, we announced:

• Two new Biostatistics and Statistical Programming contracts with a UK clinical-stage biopharma company developing immunotherapies across multiple disease areas. And we were pleased to also secure a new Biometrics contract with the Global Antibiotic R&D Partnership (GARDP) Foundation. This project will support the optimisation of efficacy trial design within GARDP’s Serious Bacterial Infections (SBIs) programme, marking an important expansion of our work into infectious disease and a further step forward for our growing Biometrics capability.

The papers and the awards

• We co-authored three papers with partners including Ankyra Therapeutics Merck KGaA, Darmstadt, Germany , and Astellas Pharma , demonstrating how MI

Antibody pembrolizumab, applying the Physiomics plc proprietary Virtual Tumour platform and a parallel QSP model developed by the Astellas team.

Beyond peer-reviewed research, we also continued to contribute to wider industry discussion.

In our collaborative blog series with Weatherden , we explored how MIDD can help drug developers align with the FDA’s evolving expectations on dose optimisation. Part 1 examined the implications of the FDA’s finalised guidance for oncology drug development, while Part 2 focused on how MIDD can support smarter, data-driven dose decisions from IND through to Phase 2.

We also shared our perspective in European Biopharmaceutical Review (EBR) , where Dr Mark Davies and Hayley Close discussed how MIDD is reshaping decision-making across the R&D pipeline. A central theme of the article was the need for greater harmonisation across teams and organisations to move MIDD from a specialist capability to an integral part of modern drug development

Good to see Sbtx above 14p once again , going ok from 12.75p, looks like the TR1 buyers was adding more before Christmas